data-depression-psiloctr/data.csv at master · metapsy-project/data-depression-psiloctr · GitHub

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
study;condition_arm1;condition_arm2;multi_arm1;multi_arm2;outcome_type;instrument;rating;instrument_symptom;primary_instrument;cov_time_point;study_time_point;time_weeks;time_days;primary_timepoint;post_crossover;n_arm1;mean_arm1;sd_arm1;n_arm2;mean_arm2;sd_arm2;n_change_arm1;mean_change_arm1;sd_change_arm1;n_change_arm2;mean_change_arm2;sd_change_arm2;event_arm1;totaln_arm1;event_arm2;totaln_arm2;baseline_m_arm1;baseline_sd_arm1;baseline_n_arm1;baseline_m_arm2;baseline_sd_arm2;baseline_n_arm2;d1;d2;d3;d4;d5;rob;year;drug_arm1;drug_arm2;dose_arm1;dose_arm2;name_arm1;name_arm2;n_dosing_sessions;mean_age;percent_women;diagnosis;target_group;design;blinding;doi;registration_number;full_ref;.id;.g;.g_se;.log_rr;.log_rr_se;.event_arm1;.event_arm2;.totaln_arm1;.totaln_arm2
Back 2024;psil;ncn;NA;NA;msd;madrs;clinician;depression;1;Pre-first dose 1;Day -8;-1,14;-8,000;0;NA;15;27,670;5,27000000000000;15;28,400;7,39000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Low;Low;Low;Low;Low;2024;psilocybin;niacin;25 mg;100 mg;psilocybin arm;niacin arm;1;38,0000000000000;50,0000000000000;dep;covid practitioners with persistent depression symptoms;parallel;double-blind;10.1001/jamanetworkopen.2024.49026;NCT05163496;Back, A. L., Freeman-Young, T. K., Morgan, L., Sethi, T., Baker, K. K., Myers, S., McGregor, B. A., Harvey, K., Tai, M., Kollefrath, A., Thomas, B. J., Sorta, D., Kaelen, M., Kelmendi, B., & Gooley, T. A. (2024). Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Network Open, 7(12), e2449026. https://doi.org/10.1001/jamanetworkopen.2024.49026;Back2024_msd_madrs_Day-8_-1.14_clinician_psil_ncn_NA_NA;-0,11066608890309594;0,365443493603394;NA;NA;NA;NA;NA;NA
Back 2024;psil;ncn;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 4;Day 28;4,00;28,000;1;NA;15;6,330;6,72000000000000;15;19,070;10,34000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Low;Low;Low;Low;Low;2024;psilocybin;niacin;25 mg;100 mg;psilocybin arm;niacin arm;1;38,0000000000000;50,0000000000000;dep;covid practitioners with persistent depression symptoms;parallel;double-blind;10.1001/jamanetworkopen.2024.49026;NCT05163496;Back, A. L., Freeman-Young, T. K., Morgan, L., Sethi, T., Baker, K. K., Myers, S., McGregor, B. A., Harvey, K., Tai, M., Kollefrath, A., Thomas, B. J., Sorta, D., Kaelen, M., Kelmendi, B., & Gooley, T. A. (2024). Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial. JAMA Network Open, 7(12), e2449026. https://doi.org/10.1001/jamanetworkopen.2024.49026;Back2024_msd_madrs_Day28_4.00_clinician_psil_ncn_NA_NA;-1,42153552640955994;0,410986356401838;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;change;qids-sr;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;30;-8,000;5,47722557505166;29;-6,000;5,38516480713450;NA;NA;NA;NA;14,500;3,90000000000000;30;16,400;4,10000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_change_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA;-0,36330936175831902;0,262611586674514;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;change;bdi-1a;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;30;-18,400;12,29581251542210;29;-10,800;9,61636572702590;NA;NA;NA;NA;29,100;6,80000000000000;30;28,700;7,00000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_change_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA;-0,67801807970489791;0,267986899585578;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;change;ham-d-17;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;30;-10,500;5,47722557505166;29;-5,100;5,38516480713450;NA;NA;NA;NA;19,200;2,30000000000000;30;18,400;3,40000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_change_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA;-0,98093527674746128;0,276026275889254;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;change;madrs;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;30;-14,400;9,31128347758782;29;-7,200;9,15478017212866;NA;NA;NA;NA;27,900;4,00000000000000;30;26,900;5,30000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_change_madrs_Week6_3.00_clinician_psil_esc_NA_NA;-0,76936100137055774;0,270125147933961;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;msd;qids-sr;self-report;depression;1;Post-second dose 1;Week 6;3,00;21,000;1;NA;30;6,900;5,90000000000000;29;10,100;5,80000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14,500;3,90000000000000;30;16,400;4,10000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_msd_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA;-0,53967873292569379;0,265237432013847;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;msd;bdi-1a;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;30;10,700;11,00000000000000;29;17,900;11,10000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29,100;6,80000000000000;30;28,700;7,00000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_msd_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA;-0,64301693596713383;0,267235040715549;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;msd;ham-d-17;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;30;8,300;5,50000000000000;29;13,600;5,20000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;19,200;2,30000000000000;30;18,400;3,40000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_msd_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA;-0,97669793075590361;0,275895471772229;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;msd;madrs;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;30;13,000;10,00000000000000;29;19,800;8,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;27,900;4,00000000000000;30;26,900;5,30000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_msd_madrs_Week6_3.00_clinician_psil_esc_NA_NA;-0,72202724206718649;0,268985534799480;NA;NA;NA;NA;NA;NA
Carhart-Harris 2021;psil;esc;NA;NA;response;qids-sr;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;30;14;29;14,500;3,90000000000000;30;16,400;4,10000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_response_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA;-0,49850120170936724;0,300373270489182;0,3715635564324830;0,226343824951325;21;14;30;29
Carhart-Harris 2021;psil;esc;NA;NA;remission;qids-sr;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;30;8;29;14,500;3,90000000000000;30;16,400;4,10000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_remission_qids-sr_Week6_3.00_self-report_psil_esc_NA_NA;-0,67099216954833840;0,306156690535671;0,7198702507006988;0,340598645707439;17;8;30;29
Carhart-Harris 2021;psil;esc;NA;NA;response;bdi-1a;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;30;12;29;29,100;6,80000000000000;30;28,700;7,00000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_response_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA;-0,83667810429445455;0,315989993146670;0,6166860144654681;0,242889897379194;23;12;30;29
Carhart-Harris 2021;psil;esc;NA;NA;remission;bdi-1a;self-report;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;30;5;29;29,100;6,80000000000000;30;28,700;7,00000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_remission_bdi-1a_Week6_3.00_self-report_psil_esc_NA_NA;-0,99934093835083038;0,338703230909486;1,1898738799464341;0,437043976571857;17;5;30;29
Carhart-Harris 2021;psil;esc;NA;NA;response;ham-d-17;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22;30;7;29;19,200;2,30000000000000;30;18,400;3,40000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_response_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA;-1,17335476888894030;0,330230008279525;1,1112307526273211;0,347124756186685;22;7;30;29
Carhart-Harris 2021;psil;esc;NA;NA;response;madrs;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;30;6;29;27,900;4,00000000000000;30;26,900;5,30000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_response_madrs_Week6_3.00_clinician_psil_esc_NA_NA;-1,10815056090644326;0,330863916168362;1,1700712526502546;0,385811579287926;20;6;30;29
Carhart-Harris 2021;psil;esc;NA;NA;remission;ham-d-17;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;30;3;29;19,200;2,30000000000000;30;18,400;3,40000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_remission_ham-d-17_Week6_3.00_clinician_psil_esc_NA_NA;-1,17485144826604637;0,391842523093344;1,5755363607584190;0,576353978077689;15;3;30;29
Carhart-Harris 2021;psil;esc;NA;NA;remission;madrs;clinician;depression;0;Post-second dose 1;Week 6;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;30;2;29;27,900;4,00000000000000;30;26,900;5,30000000000000;29;Low;Low;Low;Some concerns;Low;Some concerns;2021;psilocybin;escitalopram;25 mg;"10 mg; 20 mg";psilocybin group;escitalopram group;2;41,2355932203390;34,0508474576271;mdd;mdd;parallel;double-blind;10.1056/NEJMoa2032994;NCT03429075;Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994;Carhart-Harris2021_remission_madrs_Week6_3.00_clinician_psil_esc_NA_NA;-0,95500795088472690;0,459878100635296;1,4701758451005926;0,737085489720893;9;2;30;29
Davis 2021;psil;wl;NA;NA;msd;bdi;self-report;depression;0;Post-second dose 1;Week 5;1,00;7,000;0;0;13;8,200;8,90000000000000;11;35,200;9,10000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;7,00000000000000;13;34,500;10,00000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;mdd;mdd;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_bdi_Week5_1.00_self-report_psil_wl_NA_NA;-2,89930264844220353;0,596396246972318;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;bdi;self-report;depression;0;Post-second dose 2;Week 8;4,00;28,000;1;0;13;8,200;7,00000000000000;11;35,900;8,40000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;7,00000000000000;13;34,500;10,00000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;mdd;mdd;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_bdi_Week8_4.00_self-report_psil_wl_NA_NA;-3,48779651560760939;0,663090832701423;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;qids-sr;self-report;depression;0;Post-second dose 1;Week 5;1,00;7,000;0;0;13;5,200;4,60000000000000;11;31,900;5,60000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,200;3,60000000000000;13;17,400;3,60000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;mdd;mdd;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_qids-sr_Week5_1.00_self-report_psil_wl_NA_NA;-5,07565447275226678;0,862303533688809;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;qids-sr;self-report;depression;0;Post-second dose 2;Week 8;4,00;28,000;1;0;13;5,500;3,60000000000000;11;17,700;3,70000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,200;3,60000000000000;13;17,400;3,60000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;mdd;mdd;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_qids-sr_Week8_4.00_self-report_psil_wl_NA_NA;-3,23093088729085398;0,633341175482840;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;grid-ham-d;clinician;depression;1;Post-second dose 1;Week 5;1,00;7,000;0;0;13;8,000;7,10000000000000;11;23,800;5,40000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,900;3,60000000000000;13;22,500;4,40000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;mdd;mdd;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_grid-ham-d_Week5_1.00_clinician_psil_wl_NA_NA;-2,38972798584679724;0,543559686244671;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;grid-ham-d;clinician;depression;1;Post-second dose 2;Week 8;4,00;28,000;1;0;13;8,500;5,70000000000000;11;23,500;6,00000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,900;3,60000000000000;13;22,500;4,40000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;mdd;mdd;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_grid-ham-d_Week8_4.00_clinician_psil_wl_NA_NA;-2,48065716535764702;0,552588609503246;NA;NA;NA;NA;NA;NA
Davis 2021;psil;wl;NA;NA;msd;phq-9;self-report;depression;0;Post-second dose 2;Week 8;4,00;28,000;1;0;13;4,800;2,90000000000000;11;18,800;4,30000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,500;3,10000000000000;13;17,900;3,30000000000000;11;Low;Some concerns;Some concerns;Low;Low;Some concerns;2021;psilocybin;waitlist;"1st dose: 20 mg/70 kg; 2nd dose 30mg/70kg";NA;immediate treatment group;delayed treatment group;2;39,8666666666667;66,7777777777778;mdd;mdd;crossover;open-label;"10.1001/jamapsychiatry.2020.3285; 10.1177/02698811211073759";NCT03181529;Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285;Davis2021_msd_phq-9_Week8_4.00_self-report_psil_wl_NA_NA;-3,75018853776688310;0,694357648017136;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;79;-6,300;5,89523099107666;75;-5,200;5,96497089341323;NA;NA;NA;NA;16,100;4,14000000000000;79;16,300;4,16000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_25mg_10mg;-0,18460291306012985;0,161565177688826;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;79;-6,300;5,89523099107666;79;-3,600;6,12197064457961;NA;NA;NA;NA;16,100;4,14000000000000;79;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_25mg_1mg;-0,44711245099768004;0,161106231491561;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;75;-5,200;5,96497089341323;79;-3,600;6,12197064457961;NA;NA;NA;NA;16,300;4,16000000000000;75;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week3_3.00_self-report_psil_psil_10mg_1mg;-0,26332785116562563;0,161922629984635;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;79;-6,500;29,24941530188038;75;-5,500;7,06959513293419;NA;NA;NA;NA;16,100;4,14000000000000;79;16,300;4,16000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_25mg_10mg;-0,04622662928049439;0,161240715280361;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;79;-6,500;29,24941530188038;79;-5,000;7,02892925859141;NA;NA;NA;NA;16,100;4,14000000000000;79;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_25mg_1mg;-0,07017806878265766;0,159160900372791;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;75;-5,500;7,06959513293419;79;-5,000;7,02892925859141;NA;NA;NA;NA;16,300;4,16000000000000;75;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_qids-sr_Week12_12.00_self-report_psil_psil_10mg_1mg;-0,07058391584933107;0,161269643391451;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;79;-15,026;12,05239162987994;75;-11,986;12,23693895547412;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg;-0,24912114593171114;0,161848897621857;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;79;-15,026;12,05239162987994;79;-9,078;12,05239162987994;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg;-0,49113554613926258;0,161515313598675;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;75;-11,986;12,23693895547412;79;-9,078;12,05239162987994;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg;-0,23830404354257123;0,161795477652513;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;79;-13,043;11,12801941047912;75;-8,796;11,77794549146837;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg;-0,36911477037163343;0,162598654898194;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;79;-13,043;11,12801941047912;79;-6,887;11,59020552017953;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg;-0,53922249061526439;0,162004663914633;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;75;-8,796;11,77794549146837;79;-6,887;11,59020552017953;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg;-0,16260640126933609;0,161487655787320;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;79;-12,000;12,01720163565628;75;-7,900;11,92994178682645;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg;-0,34069351044301460;0,162395109096660;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;79;-12,000;12,01720163565628;79;-5,400;12,24394128915923;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg;-0,54143627865238364;0,162028254630371;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;75;-7,900;11,92994178682645;79;-5,400;12,24394128915923;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg;-0,20572488372314504;0,161648820099789;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;79;-11,530;13,44783815339848;75;-5,991;13,58793858537784;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg;-0,40777834306524813;0,162901252285212;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;79;-11,530;13,44783815339848;79;-6,261;12,98565204369808;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg;-0,39668059044808601;0,160683685359775;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;75;-5,991;13,58793858537784;79;-6,261;12,98565204369808;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg;0,02022736455153360;0,161223146003312;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;79;-9,339;14,37221037279931;75;-6,109;14,49726525935150;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg;-0,22268312464111339;0,161722489932522;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;79;-9,339;14,37221037279931;79;-5,322;14,38109856721662;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg;-0,27806582665982427;0,159885943110615;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;75;-6,109;14,49726525935150;79;-5,322;14,38109856721662;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg;-0,05424039656402192;0,161248901762607;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;change;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;79;-9,496;14,38109856721662;75;-5,651;14,04693204938360;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg;-0,26906891465809013;0,161953575769648;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;79;-9,496;14,38109856721662;79;-6,000;14,84328467691703;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg;-0,23807040049667147;0,159679538002117;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;change;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;75;-5,651;14,04693204938360;79;-6,000;14,84328467691703;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_change_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg;0,02401449041642934;0,161224849872201;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;79;24;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg;-0,48305875461703568;0,184601397856223;0,5076560490047115;0,198707396175270;42;24;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;42;79;18;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg;-0,73920316646147111;0,193189884520747;0,8472978603872034;0,232483598709408;42;18;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24;75;18;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg;-0,25605013073695237;0,201233919986895;0,3396418113824921;0,266890728652735;24;18;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35;79;17;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg;-0,54771974280242786;0,196758469095511;0,6701749785024865;0,247797087960611;35;17;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35;79;12;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg;-0,81804245767283490;0,213213509731684;1,0704414117014134;0,294258910160014;35;12;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;75;12;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg;-0,27021837826529371;0,230191279338547;0,4002664331989267;0,340830311978943;17;12;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;79;14;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg;-0,50860496869956251;0,207979479793817;0,6762787614405044;0,282700846952793;29;14;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;79;14;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg;-0,54351800232260727;0,207240964352298;0,7282385003712155;0,283892364027387;29;14;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;75;14;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg;-0,03484371103147465;0,230396909206025;0,0519597389307112;0,341856083280243;14;14;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;11;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg;-0,57537176793779310;0,223178286826114;0,8082415262924004;0,321526154751359;26;11;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;16;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg;-0,36121988671638899;0,203097531606742;0,4855078157817008;0,275036511694967;26;16;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;75;16;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg;0,21419795273801784;0,237075981004254;-0,3227337105106995;0,356955921267117;11;16;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;12;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg;-0,31622793564509760;0,224733656397081;0,4588658848352796;0,327630542153656;20;12;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;12;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg;-0,35004349052636913;0,224091872823937;0,5108256237659907;0,328659212007104;20;12;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;75;12;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg;-0,03377090884963717;0,244994243823549;0,0519597389307110;0,375066801363746;12;12;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;12;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg;-0,51899736264531959;0,218131110395555;0,7212301493027706;0,309521098817895;26;12;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;79;13;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg;-0,50067053597456312;0,213104169598532;0,6931471805599453;0,300113577980759;26;13;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;75;13;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg;0,01839068431471346;0,241127423028606;-0,0280829687428252;0,366421682048123;12;13;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;response;madrs;clinician;depression;1;Post-first dose 7;Week 3-12 Sustained Response;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;3;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_25mg_10mg;-0,99160609743480599;0,359674074446653;1,6220166946409604;0,608146176631818;16;3;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 7;Week 3-12 Sustained Response;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;6;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_25mg_1mg;-0,61898877394486473;0,280440753604151;0,9808292530117262;0,451497741932852;16;6;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;response;madrs;clinician;depression;1;Post-first dose 7;Week 3-12 Sustained Response;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;3;75;6;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_response_madrs_Week3-12SustainedResponse_12.00_clinician_psil_psil_10mg_1mg;0,37269627194386418;0,400458956333702;-0,6411874416292344;0,688482707712086;3;6;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;30;79;16;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg;-0,44674242736280145;0,201209101839793;0,5766489204916631;0,264275939411628;30;16;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;30;79;15;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg;-0,52684226306569792;0,203344838513193;0,6931471805599453;0,273282901594296;30;15;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;75;15;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg;-0,08003264000584821;0,221728017482283;0,1164982600682823;0,321208819127421;16;15;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;79;8;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg;-0,74343684682551936;0,245600712471635;1,0874745442576539;0,372838354811526;25;8;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;79;9;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg;-0,70294054932581040;0,236439338957101;1,0216512475319814;0,354675422625967;25;9;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;75;9;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg;0,04058595351917987;0,283986403909221;-0,0658232967256723;0,458387990603677;8;9;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;79;7;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg;-0,75912540018388175;0,257947947756852;1,1376243279431253;0,400429572515909;23;7;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;79;6;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg;-0,88273008225015182;0,271050185749346;1,3437347467010947;0,429916819675655;23;6;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;7;75;6;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg;-0,12349209492711938;0,320496322472041;0,2061104187579694;0,532477462755350;7;6;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;7;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg;-0,65382211876337593;0,261234604859298;0,9978623855679666;0,408491837954822;20;7;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;79;10;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg;-0,46621722690354056;0,234844046305309;0,6931471805599453;0,353105571046107;20;10;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;7;75;10;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg;0,18766435518260557;0,287567453972760;-0,3047152050080214;0,465688288102362;7;10;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;9;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg;-0,34116816345177042;0,249402839658612;0,5234044059728509;0,384212896620710;16;9;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16;79;9;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg;-0,37349593678986254;0,248874676341758;0,5753641449035619;0,385090450952641;16;9;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;75;9;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg;-0,03228013608197812;0,276577838141005;0,0519597389307110;0,442979300916857;9;9;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;remission;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;79;5;75;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg;-0,89045938373218436;0,291290666364917;1,3831247863586114;0,470773285603180;21;5;79;75
Goodwin 2022;psil;psil;25 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;79;9;79;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg;-0,56806969819056030;0,240481329850560;0,8472978603872034;0,365258405836137;21;9;79;79
Goodwin 2022;psil;psil;10 mg;1 mg;remission;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5;75;9;79;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_remission_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg;0,32246213956063119;0,321327108955673;-0,5358269259714080;0,533965869629957;5;9;75;79
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;79;16,874;10,53912408759124;75;21,014;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_25mg_10mg;-0,39654492550867360;0,162810289829870;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;79;16,874;10,53912408759124;79;23,622;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_25mg_1mg;-0,64668668511676197;0,163256618223517;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;75;21,014;10,53912408759124;79;23,622;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Day2_0.29_clinician_psil_psil_10mg_1mg;-0,25000147259605821;0,161853348627889;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;79;18,857;10,53912408759124;75;24,204;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_25mg_10mg;-0,51215597021615411;0,163864815195660;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;79;18,857;10,53912408759124;79;25,813;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_25mg_1mg;-0,66662012176529273;0,163512602249458;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 2;Week 1;1,00;7,000;0;NA;75;24,204;10,53912408759124;79;25,813;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week1_1.00_clinician_psil_psil_10mg_1mg;-0,15423787170516007;0,161460733330932;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;79;19,900;10,53912408759124;75;25,100;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_25mg_10mg;-0,49807575184664338;0,163722432833855;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;79;19,900;10,53912408759124;79;27,300;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_25mg_1mg;-0,70917034230350318;0,164083582263683;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 3;Week 3;3,00;21,000;1;NA;75;25,100;10,53912408759124;79;27,300;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week3_3.00_clinician_psil_psil_10mg_1mg;-0,21089081277274843;0,161670647650147;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;79;20,370;10,53912408759124;75;27,009;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_25mg_10mg;-0,63590863779035878;0,165280238538101;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;79;20,370;10,53912408759124;79;26,439;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_25mg_1mg;-0,58161551451891369;0,162472569947978;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 4;Week 6;6,00;42,000;0;NA;75;27,009;10,53912408759124;79;26,439;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week6_6.00_clinician_psil_psil_10mg_1mg;0,05463989240021171;0,161249344032070;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;79;22,561;10,53912408759124;75;26,891;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_25mg_10mg;-0,41474384721076230;0,162958905257691;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;79;22,561;10,53912408759124;79;27,378;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_25mg_1mg;-0,46163155930756411;0,161237019689574;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 5;Week 9;9,00;63,000;0;NA;75;26,891;10,53912408759124;79;27,378;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week9_9.00_clinician_psil_psil_10mg_1mg;-0,04668355719105886;0,161241146956967;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;79;22,404;10,53912408759124;75;27,349;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;33,000;6,31000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_25mg_10mg;-0,47365088324647153;0,163484580987544;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;79;22,404;10,53912408759124;79;26,700;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,900;5,41000000000000;79;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_25mg_1mg;-0,41170213385619620;0,160804375658786;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;madrs;clinician;depression;1;Post-first dose 6;Week 12;12,00;84,000;0;NA;75;27,349;10,53912408759124;79;26,700;10,22750000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;6,31000000000000;75;32,700;6,24000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_madrs_Week12_12.00_clinician_psil_psil_10mg_1mg;0,06221278976796046;0,161258341358482;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;79;9,800;5,20465116279070;75;11,100;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,100;4,14000000000000;79;16,300;4,16000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week3_3.00_self-report_psil_psil_25mg_10mg;-0,24812747376470318;0,161843892248539;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;79;9,800;5,20465116279070;79;12,200;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,100;4,14000000000000;79;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week3_3.00_self-report_psil_psil_25mg_1mg;-0,45811928515047246;0,161205007705512;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 3;Week 3;3,00;21,000;1;NA;75;11,100;5,20465116279070;79;12,200;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,300;4,16000000000000;75;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week3_3.00_self-report_psil_psil_10mg_1mg;-0,20993510179968158;0,161666568909026;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;10 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;79;9,600;5,20465116279070;75;10,800;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,100;4,14000000000000;79;16,300;4,16000000000000;75;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;10 mg;25-mg group;10-mg group;1;40,3948051948052;55,5129870129870;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week12_12.00_self-report_psil_psil_25mg_10mg;-0,22904074501357188;0,161751602527394;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;25 mg;1 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;79;9,600;5,20465116279070;79;10,800;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,100;4,14000000000000;79;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;25 mg;1 mg;25-mg group;1-mg group;1;39,4500000000000;51,0000000000000;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week12_12.00_self-report_psil_psil_25mg_1mg;-0,22905964257523606;0,159637418544292;NA;NA;NA;NA;NA;NA
Goodwin 2022;psil;psil;10 mg;1 mg;imsd;qids-sr;self-report;depression;0;Post-first dose 6;Week 12;12,00;84,000;0;NA;75;10,800;5,20465116279070;79;10,800;5,22250000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;16,300;4,16000000000000;75;15,800;3,96000000000000;79;Low;Low;Low;Low;Low;Low;2022;psilocybin;psilocybin;10 mg;1 mg;10-mg group;1-mg group;1;39,6253246753247;50,3831168831169;trd;tr-mdd;parallel;double-blind;"10.1056/NEJMoa2206443; https://doi.org/10.1016/j.jad.2023.01.108";NCT03775200;Goodwin Guy M., Aaronson Scott T., Alvarez Oscar, Arden Peter C., Baker Annie, Bennett James C., Bird Catherine, Blom Renske E., Brennan Christine, Brusch Donna, Burke Lisa, Campbell-Coker Kete, Carhart-Harris Robin, Cattell Joseph, Daniel Aster, DeBattista Charles, Dunlop Boadie W., Eisen Katherine, Feifel David, … Malievskaia Ekaterina. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443;Goodwin2022_imsd_qids-sr_Week12_12.00_self-report_psil_psil_10mg_1mg;0,00000000000000000;0,161218985176792;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;bdi;self-report;depression;0;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;26;7,000;7,08763712389397;25;12,920;7,90000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,770;8,20942141688438;26;18,400;5,45000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_bdi_5weeksaftersession1_5.00_self-report_psil_psil_22mg/kg_1mg/kg;-0,77754880367406609;0,290818652815185;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;bdi;self-report;depression;0;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;25;5,800;7,05000000000000;24;8,170;6,07473456210228;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,770;8,20942141688438;26;18,400;5,45000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_bdi_5weeksaftersession2_5.00_self-report_psil_psil_22mg/kg_1mg/kg;-0,35382339575641347;0,288073118615127;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;bdi;self-report;depression;0;Follow-up 1;6 months;26,09;182,625;0;1;24;6,170;6,17271415181361;22;8,000;7,03562363973514;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17,770;8,20942141688438;26;18,400;5,45000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_bdi_6months_26.09_self-report_psil_psil_22mg/kg_1mg/kg;-0,27257529146759862;0,296575805493764;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;grid-ham-d;clinician;depression;1;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;25;6,640;5,20000000000000;25;14,800;7,25000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-1,27311104197224201;0,311013705206831;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;grid-ham-d;clinician;depression;1;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;25;6,520;7,20000000000000;24;6,500;4,21312235758707;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg;0,00331890655475999;0,285774006447645;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;grid-ham-d;clinician;depression;1;Follow-up 1;6 months;26,09;182,625;0;1;24;6,230;6,36867333123626;22;6,950;5,81611554218105;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg;-0,11579698553577734;0,295418499944029;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;hads-d;self-report;depression;0;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;26;3,920;3,77327444005866;25;6,040;3,95000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,810;3,51832346437902;26;9,480;3,55000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_hads-d_5weeksaftersession1_5.00_self-report_psil_psil_22mg/kg_1mg/kg;-0,54065489082500096;0,285337615889013;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;hads-d;self-report;depression;0;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;25;4,280;4,45000000000000;24;4,570;3,57625502446344;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,810;3,51832346437902;26;9,480;3,55000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_hads-d_5weeksaftersession2_5.00_self-report_psil_psil_22mg/kg_1mg/kg;-0,07052468938737315;0,285865505950152;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;msd;hads-d;self-report;depression;0;Follow-up 1;6 months;26,09;182,625;0;1;24;3,460;3,23332646047380;22;4,640;3,37709934707287;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,810;3,51832346437902;26;9,480;3,55000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_msd_hads-d_6months_26.09_self-report_psil_psil_22mg/kg_1mg/kg;-0,35115579586740397;0,297504127606758;NA;NA;NA;NA;NA;NA
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;response;grid-ham-d;clinician;depression;1;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;23;25;8;25;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_response_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-1,73443550611936326;0,470184256190578;1,0560526742493137;0,297452955725044;23;8;25;25
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;response;grid-ham-d;clinician;depression;1;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21;25;18;24;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_response_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-0,30358263731036345;0,397508236769202;0,1133286853070031;0,146655843756519;21;18;25;24
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;response;grid-ham-d;clinician;depression;1;Follow-up 1;6 months;26,09;182,625;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;19;24;17;22;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_response_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg;-0,06027067386422890;0,394288867299855;0,0242142581205945;0,155993257027094;19;17;24;22
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;remission;grid-ham-d;clinician;depression;1;Post-first dose 1;5 weeks after session 1;5,00;35,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;25;4;25;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_remission_grid-ham-d_5weeksaftersession1_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-1,11990289316815228;0,375667318726251;1,3217558399823195;0,486483983977547;15;4;25;25
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;remission;grid-ham-d;clinician;depression;1;Post-second dose 1;5 weeks after session 2;5,00;35,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;25;14;24;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_remission_grid-ham-d_5weeksaftersession2_5.00_clinician_psil_psil_22mg/kg_1mg/kg;-0,22637835717215685;0,328608718760945;0,1533340199207023;0,220421038409834;17;14;25;24
Griffiths 2016;psil;psil;22 mg/kg;1 mg/kg;remission;grid-ham-d;clinician;depression;1;Follow-up 1;6 months;26,09;182,625;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;17;24;13;22;22,840;4,94604892818500;26;22,320;4,40000000000000;25;Low;Low;Low;Some concerns;High;High;2016;psilocybin;psilocybin;22 mg/kg;1 mg/kg;High-Dose-1st Group;Low-Dose-1st Group;1;56,3071428571429;49,0357142857143;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675513;NCT00465595;Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513;Griffiths2016_remission_grid-ham-d_6months_26.09_clinician_psil_psil_22mg/kg_1mg/kg;-0,28154787481164734;0,344178896486629;0,1812526096050495;0,220511664574982;17;13;24;22
Grob 2011;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Pre-first dose 1;1 day before experimental session;-0,14;-1,000;0;1;12;16,090;12,70978882594042;12;14,369;13,64856036364275;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Some concerns;Low;Some concerns;High;High;2011;psilocybin;niacin;0.2 mg/kg;250 mg;psilocybin;niacin placebo;1;NA;NA;cancer;advanced cancer patients with mood or adjustment disorder;crossover;double-blind;10.1001/archgenpsychiatry.2010.116;NCT00302744;Grob, C., Danforth, A., Chopra, G., Hagerty, M., McKay, C., Halberstadt, A., & Greer, G. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. ARCHIVES OF GENERAL PSYCHIATRY, 68(1), 71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116;Grob2011_msd_bdi_1daybeforeexperimentalsession_-0.14_self-report_psil_ncn_NA_NA;0,12600199461443884;0,408682608848014;NA;NA;NA;NA;NA;NA
Grob 2011;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 1;1 day after experimental session;0,14;1,000;0;1;12;11,442;10,04243058228435;12;13,208;11,76755318662295;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Some concerns;Low;Some concerns;High;High;2011;psilocybin;niacin;0.2 mg/kg;250 mg;psilocybin;niacin placebo;1;NA;NA;cancer;advanced cancer patients with mood or adjustment disorder;crossover;double-blind;10.1001/archgenpsychiatry.2010.116;NCT00302744;Grob, C., Danforth, A., Chopra, G., Hagerty, M., McKay, C., Halberstadt, A., & Greer, G. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. ARCHIVES OF GENERAL PSYCHIATRY, 68(1), 71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116;Grob2011_msd_bdi_1dayafterexperimentalsession_0.14_self-report_psil_ncn_NA_NA;-0,15587305359912776;0,408912757018787;NA;NA;NA;NA;NA;NA
Grob 2011;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 2;2 weeks after experimental session;2,00;14,000;1;1;12;10,054;9,25607951564808;12;13,270;10,98120211998668;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Some concerns;Low;Some concerns;High;High;2011;psilocybin;niacin;0.2 mg/kg;250 mg;psilocybin;niacin placebo;1;NA;NA;cancer;advanced cancer patients with mood or adjustment disorder;crossover;double-blind;10.1001/archgenpsychiatry.2010.116;NCT00302744;Grob, C., Danforth, A., Chopra, G., Hagerty, M., McKay, C., Halberstadt, A., & Greer, G. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. ARCHIVES OF GENERAL PSYCHIATRY, 68(1), 71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116;Grob2011_msd_bdi_2weeksafterexperimentalsession_2.00_self-report_psil_ncn_NA_NA;-0,30576069806097955;0,410799187568030;NA;NA;NA;NA;NA;NA
Krempien 2023;psil-d;psil-d;16 mg;12 mg;msd;madrs;clinician;depression;1;Post-first dose 4;Day 21;3,00;21,000;1;NA;9;16,556;6,14600000000000;15;15,867;8,68400000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,444;4,03500000000000;9;32,611;3,66400000000000;18;NA;NA;NA;NA;NA;NA;2023;CYB003 deuterated psilocin;CYB003 deuterated psilocin;16 mg;12 mg;16 mg group;12 mg group;1;NA;NA;mdd;mdd;parallel;double-blind;10.1038/s41386-023-01755-5;NCT05385783;Krempien, S., Inamdar, A., Shenouda, M., Johnson, K., Maass-Robinsin, S., Johnson, M., Kelman, A., Nathan, P., Belser, A., Pathare, P., House-Gecewicz, A., Sorie, A., Bartlone, A., Varty, G., Morgan, M., Avery, K., Muhammad, A., Nivorozhkin, A., & Palfreyman, M. (2023). Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CYB003, a Deuterated Psilocybin Analog in Patients With Major Depressive Disorder. NEUROPSYCHOPHARMACOLOGY, 48, 195–196;Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_psil-d_16mg_12mg;0,08467365452156889;0,421826984238059;NA;NA;NA;NA;NA;NA
Krempien 2023;psil-d;pcb;16 mg;NA;msd;madrs;clinician;depression;1;Post-first dose 4;Day 21;3,00;21,000;1;NA;9;16,556;6,14600000000000;9;29,000;5,31500000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;31,444;4,03500000000000;9;31,556;4,92700000000000;9;NA;NA;NA;NA;NA;NA;2023;CYB003 deuterated psilocin;placebo;16 mg;NA;16 mg group;placebo;1;NA;NA;mdd;mdd;parallel;double-blind;10.1038/s41386-023-01755-5;NCT05385783;Krempien, S., Inamdar, A., Shenouda, M., Johnson, K., Maass-Robinsin, S., Johnson, M., Kelman, A., Nathan, P., Belser, A., Pathare, P., House-Gecewicz, A., Sorie, A., Bartlone, A., Varty, G., Morgan, M., Avery, K., Muhammad, A., Nivorozhkin, A., & Palfreyman, M. (2023). Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CYB003, a Deuterated Psilocybin Analog in Patients With Major Depressive Disorder. NEUROPSYCHOPHARMACOLOGY, 48, 195–196;Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_pcb_16mg_NA;-2,06271669538168512;0,593738559711083;NA;NA;NA;NA;NA;NA
Krempien 2023;psil-d;pcb;12 mg;NA;msd;madrs;clinician;depression;1;Post-first dose 4;Day 21;3,00;21,000;1;NA;15;15,867;8,68400000000000;9;29,000;5,31500000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;32,611;3,66400000000000;18;31,556;4,92700000000000;9;NA;NA;NA;NA;NA;NA;2023;CYB003 deuterated psilocin;placebo;12 mg;NA;12 mg group;placebo;1;NA;NA;mdd;mdd;parallel;double-blind;10.1038/s41386-023-01755-5;NCT05385783;Krempien, S., Inamdar, A., Shenouda, M., Johnson, K., Maass-Robinsin, S., Johnson, M., Kelman, A., Nathan, P., Belser, A., Pathare, P., House-Gecewicz, A., Sorie, A., Bartlone, A., Varty, G., Morgan, M., Avery, K., Muhammad, A., Nivorozhkin, A., & Palfreyman, M. (2023). Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CYB003, a Deuterated Psilocybin Analog in Patients With Major Depressive Disorder. NEUROPSYCHOPHARMACOLOGY, 48, 195–196;Krempien2023_msd_madrs_Day21_3.00_clinician_psil-d_pcb_12mg_NA;-1,66123853816432954;0,489338185039199;NA;NA;NA;NA;NA;NA
Lewis 2025;psil-mbsr;mbsr;NA;NA;msd;qids-sr;self-report;depression;1;Post-first dose 1;2 weeks;2,00;14,000;1;NA;12;4,800;2,50000000000000;10;9,900;3,20000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Low;Low;Some concerns;Low;Some concerns;2025;mbsr-psilocybin;mbsr;25 mg;NA;MBSR-PAP;MBSR;1;43,6400000000000;71,8400000000000;dep;covid practitioners with burnout and depression symptoms;parallel;open-label;10.1371/journal.pmed.1004519;NCT05557643;"Lewis, B.R.; Hendrick, J.; Byrne, K.; Odette, M.; Wu, C.; Garland, E.L. (2025). Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLOS Medicine, 22. https://doi.org/10.1371/journal.pmed.1004519";Lewis2025_msd_qids-sr_2weeks_2.00_self-report_psil-mbsr_mbsr_NA_NA;-1,72973732736908947;0,506761772923200;NA;NA;NA;NA;NA;NA
Lewis 2025;psil-mbsr;mbsr;NA;NA;msd;qids-sr;self-report;depression;1;Post-first dose 2;6 months;26,09;183,000;0;NA;12;6,100;3,30000000000000;10;8,000;2,90000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;Low;Low;Low;Some concerns;Low;Some concerns;2025;mbsr-psilocybin;mbsr;25 mg;NA;MBSR-PAP;MBSR;1;43,6400000000000;71,8400000000000;dep;covid practitioners with burnout and depression symptoms;parallel;open-label;10.1371/journal.pmed.1004519;NCT05557643;"Lewis, B.R.; Hendrick, J.; Byrne, K.; Odette, M.; Wu, C.; Garland, E.L. (2025). Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLOS Medicine, 22. https://doi.org/10.1371/journal.pmed.1004519";Lewis2025_msd_qids-sr_6months_26.09_self-report_psil-mbsr_mbsr_NA_NA;-0,58466074360579112;0,437867090525376;NA;NA;NA;NA;NA;NA
Lewis 2025;psil-mbsr;mbsr;NA;NA;remission;qids-sr;self-report;depression;1;Post-first dose 2;2 weeks;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;7;13;2;12;NA;NA;NA;NA;NA;NA;Low;Low;Low;Some concerns;Low;Some concerns;2025;mbsr-psilocybin;mbsr;25 mg;NA;MBSR-PAP;MBSR;1;43,6400000000000;71,8400000000000;dep;covid practitioners with burnout and depression symptoms;parallel;open-label;10.1371/journal.pmed.1004519;NCT05557643;"Lewis, B.R.; Hendrick, J.; Byrne, K.; Odette, M.; Wu, C.; Garland, E.L. (2025). Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLOS Medicine, 22. https://doi.org/10.1371/journal.pmed.1004519";Lewis2025_remission_qids-sr_2weeks_2.00_self-report_psil-mbsr_mbsr_NA_NA;-0,94026293239993042;0,525796621133611;1,1727202608218317;0,694694704601045;7;2;13;12
Luquiens 2025;psil;psil;25 mg;1 mg;msd;bdi-ii;self-report;depression;1;Post-first dose 1;Week 3;0,00;0,000;0;NA;20;15,000;12,00000000000000;10;14,000;9,00000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;11,00000000000000;20;31,000;9,00000000000000;10;Low;High;Low;Some concerns;Low;High;2025;psilocybin;psilocybin;25 mg;1 mg;25 mg group;10 mg group;2;49,6666666666667;43,3333333333333;aud;aud inpatients with depression symptoms;parallel;double-blind;10.1111/add.70152;NCT06235411;"Luquiens, A.; Belahda, D.; Graux, C.; Igounenc, N.; Serrand, C.; Rochefort, P.; Mura, T.; Sergent, F. (2025). Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. https://doi.org/10.1111/add.70152";Luquiens2025_msd_bdi-ii_Week3_0.00_self-report_psil_psil_25mg_1mg;0,08746376594117736;0,387472166916128;NA;NA;NA;NA;NA;NA
Luquiens 2025;psil;psil;25 mg;1 mg;msd;bdi-ii;self-report;depression;1;Post-second dose 1;Week 6;3,00;21,000;1;NA;20;12,000;13,00000000000000;10;16,000;8,00000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;11,00000000000000;20;31,000;9,00000000000000;10;Low;High;Low;Some concerns;Low;High;2025;psilocybin;psilocybin;25 mg;1 mg;25 mg group;10 mg group;2;49,6666666666667;43,3333333333333;aud;aud inpatients with depression symptoms;parallel;double-blind;10.1111/add.70152;NCT06235411;"Luquiens, A.; Belahda, D.; Graux, C.; Igounenc, N.; Serrand, C.; Rochefort, P.; Mura, T.; Sergent, F. (2025). Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. https://doi.org/10.1111/add.70152";Luquiens2025_msd_bdi-ii_Week6_3.00_self-report_psil_psil_25mg_1mg;-0,33465100311620588;0,389835423511669;NA;NA;NA;NA;NA;NA
Luquiens 2025;psil;psil;25 mg;1 mg;msd;bdi-ii;self-report;depression;1;Follow-up 1;Week 12;9,00;63,000;0;NA;20;15,000;14,00000000000000;9;16,000;10,00000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;11,00000000000000;20;31,000;9,00000000000000;10;Low;High;Low;Some concerns;Low;High;2025;psilocybin;psilocybin;25 mg;1 mg;25 mg group;10 mg group;2;49,6666666666667;43,3333333333333;aud;aud inpatients with depression symptoms;parallel;double-blind;10.1111/add.70152;NCT06235411;"Luquiens, A.; Belahda, D.; Graux, C.; Igounenc, N.; Serrand, C.; Rochefort, P.; Mura, T.; Sergent, F. (2025). Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. https://doi.org/10.1111/add.70152";Luquiens2025_msd_bdi-ii_Week12_9.00_self-report_psil_psil_25mg_1mg;-0,07508793234526946;0,401514645548271;NA;NA;NA;NA;NA;NA
Luquiens 2025;psil;psil;25 mg;1 mg;response;bdi-ii;self-report;depression;1;Follow-up 1;Week 12;9,00;63,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;20;6;9;33,000;11,00000000000000;20;31,000;9,00000000000000;10;Low;High;Low;Some concerns;Low;High;2025;psilocybin;psilocybin;25 mg;1 mg;25 mg group;10 mg group;2;49,6666666666667;43,3333333333333;aud;aud inpatients with depression symptoms;parallel;double-blind;10.1111/add.70152;NCT06235411;"Luquiens, A.; Belahda, D.; Graux, C.; Igounenc, N.; Serrand, C.; Rochefort, P.; Mura, T.; Sergent, F. (2025). Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial. Addiction. https://doi.org/10.1111/add.70152";Luquiens2025_response_bdi-ii_Week12_9.00_self-report_psil_psil_25mg_1mg;0,37143752542033442;0,461274848272599;-0,2876820724517809;0,324893144826965;10;6;20;9
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;NA;NA;NA;NA;NA;NA;51;-2,700;5,10102030610204;53;-2,700;5,20007849234323;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day2_0.29_clinician_psil_ncn_NA_NA;0,00000000000000000;0,196152409277982;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;NA;NA;NA;NA;NA;NA;51;-17,800;11,84165428202259;53;-5,800;12,07161078579678;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day8_1.14_clinician_psil_ncn_NA_NA;-0,99599549798874898;0,208125264900041;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 3;Day 15;2,14;15,000;0;NA;NA;NA;NA;NA;NA;NA;51;-18,000;12,02383357866909;53;-6,900;12,62876205283355;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day15_2.14_clinician_psil_ncn_NA_NA;-0,89317763251304971;0,205835749047960;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 4;Day 29;4,14;29,000;0;NA;NA;NA;NA;NA;NA;NA;51;-19,200;12,38819217196209;53;-5,500;13,00019623085807;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day29_4.14_clinician_psil_ncn_NA_NA;-1,07046182341651752;0,209921339689726;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;madrs;clinician;depression;1;Post-first dose 5;Day 43;6,14;43,000;1;NA;NA;NA;NA;NA;NA;NA;51;-19,100;13,11690935854809;53;-6,800;13,74306458690710;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_madrs_Day43_6.14_clinician_psil_ncn_NA_NA;-0,90844823571866895;0,206161577613683;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;smdds;self-report;depression;0;Post-first dose 2;Day 8;1,14;8,000;0;NA;NA;NA;NA;NA;NA;NA;51;-21,100;14,39216443507360;48;-9,600;14,31593014419174;NA;NA;NA;NA;43,200;8,70000000000000;51;44,300;5,90000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_smdds_Day8_1.14_self-report_psil_ncn_NA_NA;-0,79488908013194914;0,209003320149336;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;change;smdds;self-report;depression;0;Post-first dose 5;Day 43;6,14;43,000;1;NA;NA;NA;NA;NA;NA;NA;50;-21,800;14,79151940237166;42;-10,800;14,38327655003785;NA;NA;NA;NA;43,200;8,70000000000000;51;44,300;5,90000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_change_smdds_Day43_6.14_self-report_psil_ncn_NA_NA;-0,74677278098618760;0,216544760098465;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 5;Day 43;6,14;43,000;1;NA;50;16,100;13,00000000000000;44;27,300;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_msd_madrs_Day43_6.14_clinician_psil_ncn_NA_NA;-0,86997194043111481;0,216378625859585;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;27;51;5;50;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Day8_1.14_clinician_psil_ncn_NA_NA;-1,26663694011237071;0,302440924827385;1,6665963262740489;0,444330050637791;27;5;51;50
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Post-first dose 3;Day 15;2,14;15,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;25;50;8;45;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Day15_2.14_clinician_psil_ncn_NA_NA;-0,83751957077186134;0,265570629110550;1,0340737675305385;0,350396600693811;25;8;50;45
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Post-first dose 4;Day 29;4,14;29,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26;49;7;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Day29_4.14_clinician_psil_ncn_NA_NA;-0,97741596097536709;0,276668227108227;1,2045557247738035;0,371730070516366;26;7;49;44
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Post-first dose 5;Day 43;6,14;43,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;29;50;9;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Day43_6.14_clinician_psil_ncn_NA_NA;-0,91915159297567650;0,259642749420353;1,0422378811403696;0,320728229198067;29;9;50;44
Raison 2023;psil;ncn;NA;NA;response;madrs;clinician;depression;1;Follow-up 1;Days 8-43 Sustained Response;6,14;43,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;48;5;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_response_madrs_Days8-43SustainedResponse_6.14_clinician_psil_ncn_NA_NA;-0,93907732959933798;0,307637231231115;1,2992829841302609;0,454356021132541;20;5;48;44
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;18;51;4;50;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Day8_1.14_clinician_psil_ncn_NA_NA;-1,00466752808606996;0,329691782803155;1,4842747694800944;0,515701185201567;18;4;51;50
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 3;Day 15;2,14;15,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;20;50;6;45;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Day15_2.14_clinician_psil_ncn_NA_NA;-0,80189679432624872;0,289456084639812;1,0986122886681098;0,417665469538056;20;6;50;45
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 4;Day 29;4,14;29,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;18;49;5;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Day29_4.14_clinician_psil_ncn_NA_NA;-0,82590432937777714;0,308672621340806;1,1733031812696990;0,460890572221842;18;5;49;44
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 5;Day 43;6,14;43,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;22;50;5;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Day43_6.14_clinician_psil_ncn_NA_NA;-0,99136754710359765;0,305383387785473;1,3537711694143306;0,450252454437811;22;5;50;44
Raison 2023;psil;ncn;NA;NA;remission;madrs;clinician;depression;1;Follow-up 1;Days 8-43 Sustained Response;6,14;43,000;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;48;4;44;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_remission_madrs_Days8-43SustainedResponse_6.14_clinician_psil_ncn_NA_NA;-0,65823804649686590;0,342583864748047;1,0116009116784799;0,538305421923955;12;4;48;44
Raison 2023;psil;ncn;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;51;32,800;13,00000000000000;53;32,300;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_imsd_madrs_Day2_0.29_clinician_psil_ncn_NA_NA;0,03893411233210140;0,196171262205403;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;51;17,700;13,00000000000000;53;29,200;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_imsd_madrs_Day8_1.14_clinician_psil_ncn_NA_NA;-0,89548458363833217;0,205884651101164;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 3;Day 15;2,14;15,000;0;NA;51;17,500;13,00000000000000;53;28,100;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_imsd_madrs_Day15_2.14_clinician_psil_ncn_NA_NA;-0,82540318144054980;0,204450551529181;NA;NA;NA;NA;NA;NA
Raison 2023;psil;ncn;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 4;Day 29;4,14;29,000;0;NA;51;16,300;13,00000000000000;53;29,500;12,50000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;35,500;5,70000000000000;51;35,000;4,50000000000000;53;Low;Low;Low;Low;Low;Low;2023;psilocybin;niacin;25 mg;100 mg;psilocybin;niacin;1;41,1134615384615;50,0576923076923;mdd;mdd;parallel;double-blind;"10.1001/jama.2023.14530; 10.1001/jama.2024.0828";NCT03866174;Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853. https://doi.org/10.1001/jama.2023.14530;Raison2023_imsd_madrs_Day29_4.14_clinician_psil_ncn_NA_NA;-1,02786056556747685;0,208879863202166;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Flexible Timepoint 1;Day -14;-2,00;-14,000;0;NA;18;12,720;8,37000000000000;19;12,210;7,75000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;aud;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day-14_-2.00_self-report_psil_pcb_NA_NA;0,06193203084870311;0,329000423326536;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 1;Day 1;0,14;1,000;0;NA;18;6,110;5,61000000000000;19;8,610;10,80000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;aud;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day1_0.14_self-report_psil_pcb_NA_NA;-0,28193258331105392;0,330619388961670;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 2;Day 14;2,00;14,000;0;NA;18;7,170;7,13000000000000;18;10,790;10,97000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;aud;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day14_2.00_self-report_psil_pcb_NA_NA;-0,38259563495698945;0,336507979084192;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 3;Day 30;4,29;30,000;1;NA;18;7,170;7,13000000000000;19;10,790;10,97000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;aud;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day30_4.29_self-report_psil_pcb_NA_NA;-0,38064430600023824;0,332012714527199;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 4;Day 96;13,71;96,000;0;NA;17;7,760;7,97000000000000;18;14,000;12,77000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;aud;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day96_13.71_self-report_psil_pcb_NA_NA;-0,56903943380207367;0,345288659722553;NA;NA;NA;NA;NA;NA
Rieser 2025;psil;pcb;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 5;Day 190;27,14;190,000;0;NA;17;9,470;10,26000000000000;17;11,410;9,68000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;13,060;8,99000000000000;18;11,050;8,02000000000000;19;Low;Low;Some concerns;Some concerns;Low;Some concerns;2025;psilocybin;mannitol;25 mg;100% mannitol;psilocybin;placebo;1;37,2675000000000;37,7975000000000;aud;aud;parallel;double-blind;10.1016/j.eclinm.2025.103149;NCT04141501;Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Rotz, R. von, Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., & Preller, K. H. (2025). Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: A phase 2 randomized clinical trial. eClinicalMedicine, 82. https://doi.org/10.1016/j.eclinm.2025.103149;Rieser2025_msd_bdi_Day190_27.14_self-report_psil_pcb_NA_NA;-0,18990696449561470;0,343807205481078;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;change;madrs;clinician;depression;1;Post-first dose 1;Day 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;16;-13,277;6,30000000000000;14;-1,064;6,20740960465797;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;tr-mdd or bipolar ii with current mde;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_change_madrs_Day1_0.14_clinician_psil_wl_NA_NA;-1,89908475272569666;0,444323125248803;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;change;madrs;clinician;depression;1;Post-first dose 2;Day 7;1,00;7,000;0;0;NA;NA;NA;NA;NA;NA;16;-11,319;7,82800000000000;14;-3,021;7,48331477354788;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;tr-mdd or bipolar ii with current mde;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_change_madrs_Day7_1.00_clinician_psil_wl_NA_NA;-1,05265203301188959;0,391710041145542;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;change;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;0;NA;NA;NA;NA;NA;NA;16;-9,600;7,60000000000000;14;-3,000;3,36749164809655;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;tr-mdd or bipolar ii with current mde;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_change_madrs_Day14_2.00_clinician_psil_wl_NA_NA;-1,06719381767744292;0,392402176392330;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;0;16;23,440;8,69000000000000;14;24,570;6,52000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;tr-mdd or bipolar ii with current mde;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_msd_madrs_Day14_2.00_clinician_psil_wl_NA_NA;-0,14171301667713440;0,366445267842868;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 1;Day 1;0,14;1,000;0;0;16;19,723;8,69000000000000;14;26,506;6,52000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;tr-mdd or bipolar ii with current mde;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_imsd_madrs_Day1_0.14_clinician_psil_wl_NA_NA;-0,85065432931062279;0,382972717203476;NA;NA;NA;NA;NA;NA
Rosenblat 2024;psil;wl;NA;NA;imsd;madrs;clinician;depression;1;Post-first dose 2;Day 7;1,00;7,000;0;0;16;21,681;8,69000000000000;14;24,549;6,52000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;33,000;3,86000000000000;16;27,570;6,64000000000000;15;Some concerns;Low;Low;High;Low;High;2024;psilocybin;waitlist;25 mg;NA;immediate group;delayed group;1;44,1266666666667;39,1333333333333;trd;tr-mdd or bipolar ii with current mde;crossover;open-label;10.1016/j.medj.2024.01.005;NCT05029466;Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190-200.e5. https://doi.org/10.1016/j.medj.2024.01.005;Rosenblat2024_imsd_madrs_Day7_1.00_clinician_psil_wl_NA_NA;-0,35967516091152402;0,369061136286049;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Pre-first dose 1;1 day pre-dose 1;-0,14;-1,000;0;0;14;10,400;6,90709953598470;15;16,247;7,54457155841205;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_1daypre-dose1_-0.14_self-report_psil_ncn_NA_NA;-0,78445040415340850;0,386427045543218;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;14;4,188;6,90709953598470;15;12,034;6,95200510644231;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,10036887261461747;0,400241252699935;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 2;2 weeks post-dose 1;2,00;14,000;0;0;14;6,636;7,15404892351178;14;13,449;7,52073134741562;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_2weekspost-dose1_2.00_self-report_psil_ncn_NA_NA;-0,90120587945026109;0,397798255450695;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 3;6 weeks post-dose 1;6,00;42,000;0;0;14;6,438;6,71627500925922;14;14,181;6,90709953598470;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_6weekspost-dose1_6.00_self-report_psil_ncn_NA_NA;-1,10350608761990276;0,407340792292258;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;12;7,097;6,39473158154429;14;12,841;7,48331477354788;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-0,79404494658719260;0,409500561347812;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-second dose 2;6 weeks post-dose 2;6,00;42,000;0;1;12;6,212;6,57486486553146;11;9,545;6,80571406980928;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_6weekspost-dose2_6.00_self-report_psil_ncn_NA_NA;-0,48050139960509808;0,423845590912223;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;bdi;self-report;depression;1;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;11;6,410;6,46078509161232;12;8,974;6,92820323027551;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,36832208305530018;0,421208871873938;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Pre-first dose 1;1 day pre-dose 1;-0,14;-1,000;0;0;14;3,859;3,47974136969977;15;5,945;3,40435236131632;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_1daypre-dose1_-0.14_self-report_psil_ncn_NA_NA;-0,58924681792804900;0,380042102654754;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;14;2,019;3,38245827764364;15;6,164;3,21070319400595;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,22287540277370277;0,406678447909128;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-first dose 2;2 weeks post-dose 1;2,00;14,000;0;0;14;2,109;3,43484148105848;14;5,831;3,43484148105848;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_2weekspost-dose1_2.00_self-report_psil_ncn_NA_NA;-1,05204046618656388;0,404752847895918;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-first dose 3;6 weeks post-dose 1;6,00;42,000;0;0;14;2,263;3,47974136969977;14;6,761;3,10183397363560;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_6weekspost-dose1_6.00_self-report_psil_ncn_NA_NA;-1,32485277849217686;0,419653953725893;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;12;2,734;3,30821704245656;14;6,101;3,28891684297429;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-0,98874905515037670;0,418101050737959;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-second dose 2;6 weeks post-dose 2;6,00;42,000;0;1;12;1,791;3,30821704245656;11;4,906;3,16737667478941;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_6weekspost-dose2_6.00_self-report_psil_ncn_NA_NA;-0,92612271955594216;0,440809253309700;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;msd;hads-d;self-report;depression;0;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;11;1,960;3,33320791430718;12;4,271;3,30821704245656;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_msd_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,67089618622880953;0,429854469566899;NA;NA;NA;NA;NA;NA
Ross 2016;psil;ncn;NA;NA;response;bdi;self-report;depression;1;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;14;4;15;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,50223974351905665;0,530033969845441;1,1676051601550610;0,441857550844268;12;4;14;15
Ross 2016;psil;ncn;NA;NA;response;bdi;self-report;depression;1;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;12;2;14;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-1,81596223568402571;0,599741779377007;1,7635885922613588;0,667261639267608;10;2;12;14
Ross 2016;psil;ncn;NA;NA;response;bdi;self-report;depression;1;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,62046695251766215;0,538490090853892;0,3383258052705359;0,282357627355504;9;7;11;12
Ross 2016;psil;ncn;NA;NA;remission;hads-d;self-report;depression;0;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;14;3;15;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,43912322147627747;0,505574636705140;1,3682758556172123;0,534927271829719;11;3;14;15
Ross 2016;psil;ncn;NA;NA;remission;hads-d;self-report;depression;0;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;12;6;14;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-0,52368289259737844;0,450158158078553;0,4418327522790392;0,370006434950477;8;6;12;14
Ross 2016;psil;ncn;NA;NA;remission;hads-d;self-report;depression;0;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,62046695251766215;0,538490090853892;0,3383258052705359;0,282357627355504;9;7;11;12
Ross 2016;psil;ncn;NA;NA;response;hads-d;self-report;depression;0;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;11;14;3;15;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_hads-d_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,43912322147627747;0,505574636705140;1,3682758556172123;0,534927271829719;11;3;14;15
Ross 2016;psil;ncn;NA;NA;response;hads-d;self-report;depression;0;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;8;12;6;14;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_hads-d_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-0,52368289259737844;0,450158158078553;0,4418327522790392;0,370006434950477;8;6;12;14
Ross 2016;psil;ncn;NA;NA;response;hads-d;self-report;depression;0;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;5,298;3,47974136969977;14;7,007;3,50117694497151;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_response_hads-d_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,62046695251766215;0,538490090853892;0,3383258052705359;0,282357627355504;9;7;11;12
Ross 2016;psil;ncn;NA;NA;remission;bdi;self-report;depression;1;Post-first dose 1;1 day post-dose 1;0,14;1,000;0;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;14;4;15;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_bdi_1daypost-dose1_0.14_self-report_psil_ncn_NA_NA;-1,50223974351905665;0,530033969845441;1,1676051601550610;0,441857550844268;12;4;14;15
Ross 2016;psil;ncn;NA;NA;remission;bdi;self-report;depression;1;Post-first dose 4;7 weeks post-dose 1 and 1 day pre-dose 2;7,00;49,000;1;0;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;10;12;2;14;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_bdi_7weekspost-dose1and1daypre-dose2_7.00_self-report_psil_ncn_NA_NA;-1,81596223568402571;0,599741779377007;1,7635885922613588;0,667261639267608;10;2;12;14
Ross 2016;psil;ncn;NA;NA;remission;bdi;self-report;depression;1;Post-second dose 3;26 weeks post-dose 2;26,00;182,000;0;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9;11;7;12;15,176;7,09792406271017;14;16,920;6,95200510644231;15;Low;Low;Low;Some concerns;Some concerns;Some concerns;2016;psilocybin;niacin;0.3 mg/kg;250 mg;Psilocybin 1st group;Niacin 1st group;1;56,0016129032258;61,1290322580645;cancer;life-threatening cancer patients with mood or adjustment disorder;crossover;double-blind;10.1177/0269881116675512;NCT00957359;Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/10.1177/0269881116675512;Ross2016_remission_bdi_26weekspost-dose2_26.00_self-report_psil_ncn_NA_NA;-0,62046695251766215;0,538490090853892;0,3383258052705359;0,282357627355504;9;7;11;12
Ross 2025;psil;ncn;NA;NA;msd;hads-d;self-report;depression;1;Post-first dose 1;Day 1;0,14;1,000;0;0;17;6,590;4,46000000000000;18;8,500;3,57000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,880;3,48000000000000;17;11,670;3,27000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;life-threatening cancer patients with precipitated psychological distress;crossover;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_hads-d_Day1_0.14_self-report_psil_ncn_NA_NA;-0,46353334402311136;0,342919999984711;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;hads-d;self-report;depression;1;Post-first dose 2;Week 3;3,00;21,000;0;0;17;6,570;4,70000000000000;18;9,280;3,92000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,880;3,48000000000000;17;11,670;3,27000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;life-threatening cancer patients with precipitated psychological distress;crossover;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_hads-d_Week3_3.00_self-report_psil_ncn_NA_NA;-0,61354207410417083;0,346427109292292;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;hads-d;self-report;depression;1;Post-first dose 3;Week 6-7;6,00;42,000;1;0;14;4,840;4,26000000000000;18;8,380;4,10000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;9,880;3,48000000000000;17;11,670;3,27000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;life-threatening cancer patients with precipitated psychological distress;crossover;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_hads-d_Week6-7_6.00_self-report_psil_ncn_NA_NA;-0,82750220689741383;0,371811877928267;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;bdi-ii;self-report;depression;0;Post-first dose 1;Day 1;0,14;1,000;0;0;17;11,900;9,31000000000000;18;17,200;8,26000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21,000;7,18000000000000;17;22,700;7,61000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;life-threatening cancer patients with precipitated psychological distress;crossover;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_bdi-ii_Day1_0.14_self-report_psil_ncn_NA_NA;-0,58949991240284649;0,345801894681828;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;bdi-ii;self-report;depression;0;Post-first dose 2;Week 3;3,00;21,000;0;0;17;12,400;8,09000000000000;18;18,800;9,61000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21,000;7,18000000000000;17;22,700;7,61000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;life-threatening cancer patients with precipitated psychological distress;crossover;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_bdi-ii_Week3_3.00_self-report_psil_ncn_NA_NA;-0,70220007394235073;0,348937266321390;NA;NA;NA;NA;NA;NA
Ross 2025;psil;ncn;NA;NA;msd;bdi-ii;self-report;depression;0;Post-first dose 3;Week 6-7;6,00;42,000;1;0;14;9,230;5,72000000000000;18;19,100;7,10000000000000;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;21,000;7,18000000000000;17;22,700;7,61000000000000;18;Low;Low;Low;Some concerns;Low;Some concerns;2025;psilocybin;niacin;25 mg;100 mg;psilocybin;placebo;1;55,9628571428571;54,5428571428571;cancer;life-threatening cancer patients with precipitated psychological distress;crossover;double-blind;10.1016/j.genhosppsych.2025.08.001;ACTRN12619001225101;"Ross, M.L.; Iyer, R.; Williams, M.L.; Boughey, M.; O'Callaghan, C.; Hiscock, R.; Dwyer, J. (2025). Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. General Hospital Psychiatry, 96. https://doi.org/10.1016/j.genhosppsych.2025.08.001";Ross2025_msd_bdi-ii_Week6-7_6.00_self-report_psil_ncn_NA_NA;-1,47160897825765136;0,403230724263689;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;Pre-first dose 1;Day -1;-0,14;-1,000;0;NA;26;25,695;6,31768517734146;26;24,798;10,01957334420982;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day-1_-0.14_self-report_psil_pcb_NA_NA;0,10548091002400753;0,277548842334483;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;DOSE 1;Day 0;0,00;0,000;0;NA;26;12,242;7,18961751416583;26;20,191;10,89150568103419;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day0_0.00_self-report_psil_pcb_NA_NA;-0,84840536845533920;0,289926959286354;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;Post-first dose 1;Day 2;0,29;2,000;0;NA;26;11,823;8,93348218781456;26;22,293;11,76853703737215;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day2_0.29_self-report_psil_pcb_NA_NA;-0,98703435264889661;0,294244283502394;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;Post-first dose 2;Day 8;1,14;8,000;0;NA;26;13,584;11,54927919828766;26;21,148;11,54927919828766;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day8_1.14_self-report_psil_pcb_NA_NA;-0,64505929083009739;0,284688371674402;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;bdi;self-report;depression;0;Post-first dose 3;Day 14;2,00;14,000;1;NA;26;13,379;10,23883118329431;26;20,729;11,33002135920317;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_bdi_Day14_2.00_self-report_psil_pcb_NA_NA;-0,67040650657638035;0,285268239079986;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;Pre-first dose 1;Day -1;-0,14;-1,000;0;NA;26;23,534;4,18629502065968;26;24,948;7,44456848984546;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day-1_-0.14_clinician_psil_pcb_NA_NA;-0,23060285431836317;0,278298712350879;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;DOSE 1;Day 0;0,00;0,000;0;NA;26;11,727;7,21511261173379;26;21,034;9,53516649041851;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day0_0.00_clinician_psil_pcb_NA_NA;-1,08416213909409986;0,297613339412923;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 1;Day 2;0,29;2,000;0;NA;26;9,775;7,90857926558241;26;20,632;11,16685273476820;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day2_0.29_clinician_psil_pcb_NA_NA;-1,10515607016573902;0,298377744492480;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 2;Day 8;1,14;8,000;0;NA;26;12,065;8,83660081705630;26;19,957;10,46828706140599;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day8_1.14_clinician_psil_pcb_NA_NA;-0,80242972515504940;0,288626644278412;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;msd;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;NA;26;11,162;9,76972138804378;26;20,696;10,23883118329431;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_msd_madrs_Day14_2.00_clinician_psil_pcb_NA_NA;-0,93836788231098855;0,292661784694183;NA;NA;NA;NA;NA;NA
von Rotz 2023;psil;pcb;NA;NA;response;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;15;26;4;26;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_response_madrs_Day14_2.00_clinician_psil_pcb_NA_NA;-1,09412740860668056;0,371085838569234;1,3217558399823193;0,489636180999311;15;4;26;26
von Rotz 2023;psil;pcb;NA;NA;remission;madrs;clinician;depression;1;Post-first dose 3;Day 14;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;26;3;26;24,118;5,11431657213356;26;24,528;6,74600281648325;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_remission_madrs_Day14_2.00_clinician_psil_pcb_NA_NA;-1,18976883955491308;0,401968864868958;1,5404450409471488;0,572572115841165;14;3;26;26
von Rotz 2023;psil;pcb;NA;NA;response;bdi;self-report;depression;0;Post-first dose 3;Day 14;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;14;26;3;26;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_response_bdi_Day14_2.00_self-report_psil_pcb_NA_NA;-1,18976883955491308;0,401968864868958;1,5404450409471488;0,572572115841165;14;3;26;26
von Rotz 2023;psil;pcb;NA;NA;remission;bdi;self-report;depression;0;Post-first dose 3;Day 14;2,00;14,000;1;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;NA;12;26;3;26;26,541;6,31768517734146;26;25,900;10,02467236372342;26;Low;Low;Low;Some concerns;Low;Some concerns;2023;psilocybin;mannitol;0.215 mg/kg;NA;psilocybin group;placebo group;1;36,7500000000000;63,4500000000000;mdd;mdd;parallel;double-blind;10.1016/j.eclinm.2022.101809;NCT03715127;von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809;vonRotz2023_remission_bdi_Day14_2.00_self-report_psil_pcb_NA_NA;-1,02235583542038633;0,401968864868958;1,3862943611198906;0,582875278034323;12;3;26;26